Sodium fusidate in Gillain-Barré syndrome: a case report.
A patient with Guillain-Barré syndrome is reported on who responded favourably to a short course treatment with the novel immunosuppressant sodium fusidate (Fucidin), given at a daily dose of 1.5 g for one week. Along with prompt and clear cut clinical improvement, treatment with Fucidin was associated with a rapid decline in the blood concentrations of inflammatory cytokines presumably implicated in the pathogenesis of Guillain-Barré syndrome such as interleukin-2, interferon-gamma, and tumor necrosis factor-alpha. The ex vivo production of these cytokines was also markedly diminished compared with pretreatment values. Fucidin was well tolerated and no clinical or biochemical side effects were seen.
Nicoletti
F
F
Institute of Microbiology, University of Milan, Italy. fnicol@herganet.it
Nicoletti
A
A
Giuffrida
S
S
Di Marco
R
R
Meroni
P
P
Bendtzen
K
K
Lunetta
M
M
D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005672:Fusidic Acid / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000097:blood; D007376:Interleukin-2 / Q000097:blood; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D011129:Polyradiculoneuropathy / Q000188:drug therapy* / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D007166:Immunosuppressive Agents; D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha; D005672:Fusidic Acid; D007371:Interferon-gamma